Literature DB >> 12519858

Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro.

Richard A Feelders1, Steven W J Lamberts, Leo J Hofland, Peter M van Koetsveld, Miriam Verhoef-Post, Axel P N Themmen, Frank H de Jong, H Jaap Bonjer, Adrian J Clark, Aart-Jan van der Lely, Wouter W de Herder.   

Abstract

In a substantial part of adrenal adenomas and hyperplasias from patients with Cushing's syndrome, cortisol production is controlled by the expression of aberrant hormone receptors on adrenocortical cells. We present in vivo and in vitro data of two patients with a LH-responsive Cushing's syndrome based on ACTH-independent bilateral adrenal hyperplasia. Patients 1 and 2 are women who presented with Cushing's syndrome and bilateral adrenal hyperplasia. Endocrine testing demonstrated absence of cortisol diurnal rhythm, insufficient cortisol suppression after 1 mg dexamethasone orally, and undetectable ACTH levels in both patients. Both patients were treated by laparoscopic biadrenalectomy. In in vivo testing, in patients 1 and 2, a profound cortisol rise was found after administration of GnRH [change in cortisol (Delta F), 118 and 106%, respectively], human CG (Delta F, 133 and 44%), LH (Delta F, 73 and 43%), ACTH (Delta F, 89 and 181%), and the 5-hydroxy-tryptamine receptor type 4 (5-HT(4)) agonists cisapride (Delta F, 141 and 148%) and metoclopramide (Delta F, 189 and 95%). In in vitro testing, adrenal cells from patient 2 responded, in a dose-dependent fashion, with cortisol production after exposure to human CG (Delta F, 45%), cisapride (Delta F, 68%), and metoclopramide (Delta F, 81%). ACTH induced cortisol production by cells from both patients (Delta F, 135 and 159%). In receptor studies, LH receptor mRNA was demonstrated in adrenal tissue of both patients but also in control adrenal tissue of two patients with persisting pituitary-dependent Cushing's syndrome treated by biadrenalectomy. In neither patient were mutations found in the ACTH receptor gene. LH-responsive Cushing's syndrome associated with bilateral adrenal hyperplasia may result from aberrant (or possibly increased) adrenal LH receptor expression. This variant is further characterized by adrenal responsiveness to 5-HT4 receptor agonists, possibly pointing to an interaction between LH and serotonin in the regulation of cortisol secretion. Despite the regulatory potential of LH and 5-HT4 receptor agonists on cortisol production in our patients, their adrenals seemed to be still sensitive to ACTH, both in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519858     DOI: 10.1210/jc.2002-020621

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Adrenocorticotropin-independent Cushing's syndrome in pregnancy related to overexpression of adrenal luteinizing hormone/human chorionic gonadotropin receptors.

Authors:  E Rask; E Schvarcz; P Hellman; J Hennings; F A Karlsson; C V Rao
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

Review 2.  Aberrant expression of hormone receptors in adrenal Cushing's syndrome.

Authors:  Stavroula Christopoulos; Isabelle Bourdeau; André Lacroix
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

3.  Successful Treatment of Estrogen Excess in Primary Bilateral Macronodular Adrenocortical Hyperplasia with Leuprolide Acetate.

Authors:  Fady Hannah-Shmouni; Andreas G Moraitis; Vladimir Valera Romero; Fabio R Faucz; Spyridon A Mastroyannis; Annabel Berthon; Richard A Failor; Maria Merino; Andrew P Demidowich; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2017-11-28       Impact factor: 2.936

4.  Luteinizing hormone correlates with adrenal function in postmenopausal women.

Authors:  Aditi R Saxena; Ellen W Seely
Journal:  Menopause       Date:  2012-11       Impact factor: 2.953

5.  Adrenal androgen concentrations increase during infancy in male rhesus macaques (Macaca mulatta).

Authors:  A J Conley; T M Plant; D H Abbott; B C Moeller; S D Stanley
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-09-06       Impact factor: 4.310

6.  Transgenic GATA-4 expression induces adrenocortical tumorigenesis in C57Bl/6 mice.

Authors:  Marcin Chrusciel; Susanna Vuorenoja; Bidut Mohanty; Adolfo Rivero-Müller; Xiangdong Li; Jorma Toppari; Ilpo Huhtaniemi; Nafis A Rahman
Journal:  J Cell Sci       Date:  2013-02-26       Impact factor: 5.285

7.  Case report: Adrenal LH/hCG receptor overexpression and gene amplification causing pregnancy-induced Cushing's syndrome.

Authors:  Michael Herman Chui; Michael Herman Chui; Nese Colak Ozbey; Shereen Ezzat; Yersu Kapran; Yesim Erbil; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

8.  Adrenal cortex stimulation with hCG in spayed female dogs with Cushing's syndrome: Is the LH-dependent variant possible?

Authors:  Ignacio M Espiñeira; Patricia N Vidal; María C Ghersevich; Elber A Soler Arias; Fernanda Bosetti; María F Cabrera Blatter; Diego D Miceli; Víctor A Castillo
Journal:  Open Vet J       Date:  2021-06-29

Review 9.  Cell-to-cell communication in bilateral macronodular adrenal hyperplasia causing hypercortisolism.

Authors:  Hervé Lefebvre; Céline Duparc; Gaëtan Prévost; Jérôme Bertherat; Estelle Louiset
Journal:  Front Endocrinol (Lausanne)       Date:  2015-04-20       Impact factor: 5.555

10.  ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase.

Authors:  Johannes Hofland; Leo J Hofland; Peter M van Koetsveld; Jacobie Steenbergen; Wouter W de Herder; Casper H van Eijck; Ronald R de Krijger; Francien H van Nederveen; Maarten O van Aken; Johannes W de Groot; Thera P Links; Frank H de Jong; Richard A Feelders
Journal:  Orphanet J Rare Dis       Date:  2013-09-13       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.